EyePoint Announces Participation at Upcoming Investor Conferences
Rhea-AI Summary
EyePoint Pharmaceuticals (NASDAQ:EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in three major upcoming investor conferences in September 2025.
The company will participate in fireside chats at Citi's 2025 BioPharma Back to School Conference on September 2 at 2:30 p.m. ET and the Cantor Global Healthcare Conference on September 3 at 2:45 p.m. ET. Additionally, management will conduct one-on-one investor meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9. Webcasts of the presentations will be available on EyePoint's website.
Positive
- None.
Negative
- None.
News Market Reaction – EYPT
In the Aug 26 session, EYPT gained 3.88%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:
- Citi’s 2025 BioPharma Back to School Conference
Forum: Fireside Chat
Date: Tuesday, September 2, 2025
Time: 2:30 p.m. ET
- Cantor Global Healthcare Conference
Forum: Fireside Chat
Date: Wednesday, September 3, 2025
Time: 2:45 p.m. ET - Morgan Stanley 23rd Annual Global Healthcare Conference
Forum: 1x1 Investor Meetings
Date: Tuesday, September 9, 2025
A live webcast and subsequent archived replay of the presentations may be accessed via the Investors section of the Company website at www.eyepointpharma.com.
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data to date, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with topline data anticipated in 2026. DURAVYU also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD is the leading cause of vision loss among people 50 years of age and older in the United States.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product candidate; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
